Inserm Research Director
Inserm Unit 791, “Laboratory of Osteoarticular and Dental Tissue Engineering”
+33 (0)2 40 41 29 16
Our spinal column is made up of a stack of vertebrae. Its articulation and flexibility are made possible by the presence of intervertebral discs that form “cushions” between the vertebrae. Degenerative diseases of the vertebral discs are related to the strong and repetitive demands made on the spinal column throughout life—carrying loads, sports, repetitive movements and twisting motions. With time, the discs become worn and deteriorate, and can no longer play their role as shock absorbers. Although these conditions appear slowly and progressively, they soon manifest as pain in the area where the discs are damaged. It is estimated that degeneration of the intervertebral discs is responsible for approximately 40% of lumbar pain. Current research is therefore aimed at developing treatments to slow or prevent the degeneration of the discs and the cells that constitute them.
From a physiological standpoint, the nucleus pulposus, the central part of the intervertebral disc, is the first to be affected. It is largely made up of water, which gives it its shock-absorbing properties. With age, the cells of the nucleus pulposus gradually become less proliferative, and are then subject to apoptosis and unable to produce this famous highly hydrated extracellular matrix.
How then can they be replaced with functional cells? The researchers focused on the adipose tissue, which constitutes a large reservoir of stem cells that can differentiate into a vast array of cell types. It was also necessary to find the right protocol to successfully enable stem cells from the adipose tissue to become transformed into nucleus pulposus cells.
A finely tuned recipe
The development of this protocol can be compared to a food recipe. The researchers were able to find the right ingredients and correct proportions for it to succeed. The winning strategy involved adding a combination of two growth factors, TGFβ and GDF5, to the cell medium. In 28 days the researchers obtained in vitro, from adipose tissue taken from nine patients, functional nucleus pulposus cells resembling those that exist naturally in the intervertebral discs.
However, we had to go further, since these cells had no chance of survival if they were merely reimplanted into a damaged intervertebral disc, without all the nutrient substrate they need.”
The second trick was therefore to couple these cells to a synthetic biomaterial to recreate a favourable environment for their multiplication once they had been injected into the intervertebral disc. The researchers assessed the biological activity of these cells in vivo after transplanting them into mice. “This system most closely resembles intradiscal transplantation in humans. We have demonstrated that the protocol we apply to these cells was sufficient for them to retain their specific secretory activity and their specialised phenotype when reinjected in vivo.”
This work in regenerative medicine now allows the researchers to contemplate the next step before moving to the clinical setting: testing the therapeutic efficacy of these brand-new cells in a relevant animal model of degenerative vertebral disc disease.
(c) S Renaudin/le Design de Solène for Inserm
The French Plan for Genomic Medicine 2025 was presented to Prime Minister Manuel Valls by Yves Lévy, President of the National Alliance for Life Sciences and Health (Aviesan) and CEO of Inserm, on 22 June 2016. ...
TGF-β1 and GDF5 act synergistically to drive the differentiation of human adipose stromal cells towards nucleus pulposus-like cells.
Pauline Colombier 1, 2, Johann Clouet1,2,3,4, Cecile Boyer 1,2, Maeva Ruel 1,2, Gaelle Bonin 1,2, Julie Lesoeur 1,2, Anne Moreau 5,6, Borhane-Hakim Fellah 1,2,7, Pierre Weiss 1,2,8, Laurent Lescaudron 1,2,9, Anne Camus1,2* and Jerome Guicheux 1,2,8*.
1INSERM UMRS 791, Laboratory of Osteoarticular and Dental Tissue Engineering,
2Université de Nantes, Training and Research Unit (UFR) for Odontology, Nantes.
3Université de Nantes, UFR for
Biological and Pharmaceutical Sciences, Nantes.
4Nantes University Hospital (CHU Nantes), Central Pharmacy, Hospital-University Hub (PHU) Nantes
5Université de Nantes, UFR for Medicine, Nantes.
6CHU Nantes, Department of Pathology, Nantes.
7CRIP, Centre for Preclinical Research and Investigation, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering (ONIRIS), Nantes.
8CHU Nantes, PHU 4 OTONN, Nantes.
9Université de Nantes, UFR for Sciences and Techniques, Nantes.